Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi to Cut 1,500-2,000 Jobs in France - Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2012 | 02:11pm CEST

French pharmaceutical giant Sanofi SA (SAN.FR, SNY) will disclose cuts of between 1,500 and 2,000 jobs in France on Sept. 25, French newspaper Le Figaro reported Saturday, without citing sources.

The company plans to reduce its 28,000 payroll in France mainly through attrition, the newspaper said.

In July, Sanofi had said it planned to cut jobs at two French units in a bid to preserve the company's profitability, which has been put at risk by recent patent expirations and the economic recession in most of Europe. The company had said it would detail the job cuts in September.

At the time, French Industry Minister Arnaud Montebourg had criticized the company and said he wouldn't tolerate when profitable companies slash jobs.

A Sanofi spokesman didn't return a phone call seeking comments.

Newspaper Web site: http://www.lefigaro.fr

Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10/19 SANOFI : - More than 30 Presentations of New Investigational Data from Sanofi : ..
10/18 SANOFI : earmarks 170m for new French vaccines facility
10/18 SANOFI SA (ADR)(NYSE : SNY), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Dupixen..
10/18 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10/18 SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17 AIMMUNE THERAPEUTICS : Announces Clinical Collaboration to Study AR101 with Rege..
10/17 SANOFI : New influenza vaccine facility, first of its kind in France
10/17 ROCHE : Cambridge biotech signs deal to take on superbugs
10/17 AIMMUNE THERAPEUTICS : Regeneron/Sanofi, Aimmune collaborate on peanut allergy c..
More news
News from SeekingAlpha
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
10/16 MANNKIND CORPORATION : Can Afrezza Improved Labeling Fuel A Successful Comeback?
10/16 Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophi..
Financials (€)
Sales 2017 36 186 M
EBIT 2017 9 602 M
Net income 2017 8 042 M
Debt 2017 5 004 M
Yield 2017 3,58%
P/E ratio 2017 13,08
P/E ratio 2018 17,56
EV / Sales 2017 3,09x
EV / Sales 2018 3,01x
Capitalization 107 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 87,0 €
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI9.90%125 891
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214